01801 INNOVENT BIO

Watchlist

40.550
+0.100+0.25%

Noon Break Mar 3 11:57 CST

66.43BMarket Cap-47.32P/E (TTM)

About INNOVENT BIO Company

Cinda Biopharmaceutical Group was founded in 2011 with the mission and goal of developing high-quality biopharmaceuticals that ordinary people can use. The company has grown into a leading biopharmaceutical company and has built a fully integrated biopharmaceutical platform that meets global quality standards, integrating R&D, clinical development, manufacturing and commercialization capabilities. The company is committed to developing, producing and selling innovative drugs for major diseases such as oncology, CVM, autoimmunity, and ophthalmology. The company has established a rich product pipeline covering a range of innovative drug forms (including monoclonal antibodies, multispecific antibodies, immunocytokines, ADC, cell therapy and small molecule drugs). “Beginning with trust, achieving action”, the company adheres to the highest standards of industry standards, and hopes to work with industry colleagues to promote the development of the biopharmaceutical industry to meet the broad demand for first-class pharmaceuticals.

Company Profile

Symbol01801

Company NameINNOVENT BIO

ISINKYG4818G1010

Listing DateOct 31, 2018

Issue Price13.98

Shares Offered236.35M share(s)

FoundedApr 28, 2011

Registered AddressCayman Islands

Chairmandechao yu

Secretaryyanjuchenluoer wang

Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants

Company CategoryOverseas registration of Mainland Individuals control

Registered OfficeMaples Corporate Services Limited PO Box 309, Ugland House, Grand Cayman KY1-1104 Cayman Islands

Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong

Fiscal Year Ends12-31

Employees5263

MarketHong Kong motherboard

Phone(86)051269566088

Fax(86)0512695660888348

Emailir@innoventbio.com

Websitehttp://www.innoventbio.com

Business Cinda Biopharmaceuticals is an investment holding company engaged in drug R&D, production and sales. The company provides medicines to treat diseases such as oncology, cardiovascular and metabolic (CVM), autoimmune, and ophthalmology. The company's product portfolio includes dabershu (cindirizumab injection), daberizumab (bevacizumab injection), sulisin (adalimumab injection), dabroximab (rituximab injection), dabotan (pemitinib tablets), etc.

Company Executives

Name
Position
Salary

dechao yu
Presidencies, CEOs, President, Executive Director, Chairman of the Strategy Committee, Nomination Committee Members
36.44M

hao xi
Executive Director, Strategy Committee Members, Authorized Representative
7.10M

qian zhang
Executive Director, Strategy Committee Members
--

Charles Leland Cooney
Independent Non-Executive Director, Audit Committee Members, Strategy Committee Members, Nomination Committee Members
--

yiyin xu
Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Chairman
400.00K

Gary Zieziula
Independent Non-Executive Director, Strategy Committee Members, Audit Committee Members, Remuneration Committee Members
--

shuyun chen
Independent Non-Executive Director, Chairman of the Nomination Committee, Strategy Committee Members, Audit Committee Members, Remuneration Committee Members
--